Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;123(2):142-6.
doi: 10.1111/j.1600-0404.2010.01430.x. Epub 2010 Oct 10.

Efficacy and safety of intravenous lacosamide in refractory nonconvulsive status epilepticus

M Z Koubeissi  1 , C L Mayor, B Estephan, S Rashid, N J Azar
Affiliations

Efficacy and safety of intravenous lacosamide in refractory nonconvulsive status epilepticus

M Z Koubeissi et al. Acta Neurol Scand. 2011 Feb.

Abstract

Background: Lacosamide (LCM) is a novel antiepileptic drug (AED) recently approved as an adjunctive therapy in the treatment of partial seizures in adults. LCM is available in oral and intravenous formulations, has linear pharmacokinetics and a unique mechanism of action.

The aim of this study: To evaluate the safety and efficacy of intravenous LCM in the treatment of nonconvulsive status epilepticus (NCSE) after failure of conventional therapy.

Methods: We retrospectively reviewed all patients with NCSE treated with LCM. We reviewed the clinical and electrographic changes before and after LCM administration. We also noted any reported side effects including electrocardiographic changes.

Results: We report four cases of NCSE that were refractory to conventional treatment, but readily responsive to LCM. No side effects attributable to LCM were identified.

Conclusions: Intravenous LCM may be safe and efficacious as an add-on AED for the treatment of NCSE when standard therapy fails.

PubMed Disclaimer

LinkOut - more resources